Finnish iCell

iCell Gene Therapeutics is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) cell therapies for cancer and autoimmune diseases. The company utilizes its proprietary Compound CAR (cCAR) and multi-target platforms to address tumor heterogeneity and prevent antigen escape, which are common causes of relapse in traditional CAR-T treatments. Their pipeline includes several first-in-class programs targeting hematological malignancies such as AML and T-ALL, as well as solid tumors and severe autoimmune conditions. iCell operates with a global footprint, conducting clinical trials in both the United States and Asia to accelerate the delivery of curative cell therapies to patients.